Results 141 to 150 of about 80,955 (206)

GSK3β guides chromosomal repair pathway selection to support BRCA1-independent PARP inhibitor sensitivity. [PDF]

J Clin Invest
Leung JW, Gius D.
europepmc   +1 more source

Evaluating carboplatin and PARP inhibitor combination efficacy using high-grade serous carcinoma spheroids and organoids. [PDF]

Cancer Biol Ther
Tomas EJ, Davis J, Ramos Valdes Y, Shepherd TG.   +3 more
europepmc   +1 more source

Unmatched Cell Line Collections Are Not Optimal for Identification of PARP Inhibitor Response and Drug Synergies. [PDF]

J Cell Mol Med
Phan Z, Fernandez KJ, Caldon CE.
europepmc   +1 more source

Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. [PDF]

Elife
Zhang Y, Xu M, Yuan J, Hu Z, Jiang J, Sun Y, Huang J, Wang Y, Wang B, Shen J, Long M, Fan Y, Montone KT, Tanyi J, Kim SH, Tavana O, Vonderheide RH, Chan HM, Domchek S, Zhang L, Hu X.   +20 more
europepmc   +1 more source

The PARP inhibitor olaparib promotes senescence in murine macrophages. [PDF]

Geroscience
Kieronska-Rudek A, Zuhra K, Ascenção K, Chlopicki S, Szabo C.   +4 more
europepmc   +1 more source

LINC00467 mediates PARP inhibitor resistance in high-grade serous ovarian cancer by regulating miR-485-5p/RAD50 axis. [PDF]

J Ovarian Res
Li X, Xiang Y, Gao J, Zong H, Li M, Gao R, Zhang H.   +6 more
europepmc   +1 more source

Genome-wide CRISPR-Cas9 screening identifies CLK1 inhibition as a strategy to restore PARP inhibitor sensitivity via ERCC1 isoform switching. [PDF]

Protein Cell
Liu C, Xu F, Wu Y, Li J, Ni M, Xia S, Chen L, Zhao H, Yu M, Zhou Y, Zhang M, Li J, Wu X, Huang Y, Zhu T, Chen X.   +15 more
europepmc   +1 more source

Dual FAK and EPHA2 targeting by brigatinib tackles PARP inhibitor adaptive survival response in high-grade serous ovarian cancer. [PDF]

Sci Transl Med
Duffield JR, Hou X, Wilson BW, Prasad A, McKeon-Makki IK, Huehls AM, Wu X, Correia C, Larson MC, Couch FJ, Oberg AL, Kaufmann SH, Karnitz LM, Weroha SJ, Kanakkanthara A.   +14 more
europepmc   +1 more source

Preclinical synergistic effects when combining a radiolabelled HER2-targeting single domain antibody with PARP inhibitor Olaparib. [PDF]

J Transl Med
Dewulf J, Navarro L, Dumauthioz N, Berdal M, Nagachinta S, Gaspariunaite V, Pombo Antunes AR, Lahoutte T, Massa S, Devoogdt N, D'Huyvetter M.   +10 more
europepmc   +1 more source